Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C.

Molleston JP, Mellman W, Narkewicz MR, Balistreri WF, Gonzalez-Peralta RP, Jonas MM, Lobritto SJ, Mohan P, Murray KF, Njoku D, Rosenthal P, Barton BA, Talor MV, Cheng I, Schwarz KB, Haber BA; PEDS-C Clinical Research Network.

J Pediatr Gastroenterol Nutr. 2013 Mar;56(3):304-10. doi: 10.1097/MPG.0b013e3182774cae.

PMID:
23439301
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Addition of pentoxifylline to pegylated interferon-alpha-2a and ribavirin improves sustained virological response to chronic hepatitis C virus: a randomized clinical trial.

Jiménez-Luévano MÁ, Lerma-Díaz JM, Hernández-Flores G, Jiménez-Partida MÁ, Bravo-Cuellar A.

Ann Hepatol. 2013 Mar-Apr;12(2):248-55.

PMID:
23396736
[PubMed - indexed for MEDLINE]
3.

Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.

Friedrich-Rust M, Theobald J, Zeuzem S, Bojunga J.

J Viral Hepat. 2009 Mar;16(3):168-77. doi: 10.1111/j.1365-2893.2008.01059.x. Epub 2008 Oct 17.

PMID:
19175874
[PubMed - indexed for MEDLINE]
4.

Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.

Alsaran K, Sabry A, Shaheen N.

Int Urol Nephrol. 2011 Sep;43(3):865-73. doi: 10.1007/s11255-010-9756-1. Epub 2010 May 19.

PMID:
20490669
[PubMed - indexed for MEDLINE]
5.

Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.

Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.

J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.

PMID:
23806058
[PubMed - indexed for MEDLINE]
Free Article
6.

The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.

Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, Rosenthal P, Mohan P, Balistreri WF, Narkewicz MR, Smith L, Lobritto SJ, Rossi S, Valsamakis A, Goodman Z, Robuck PR, Barton BA; Peds-C Clinical Research Network.

Gastroenterology. 2011 Feb;140(2):450-458.e1. doi: 10.1053/j.gastro.2010.10.047. Epub 2010 Oct 28.

PMID:
21036173
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alpha.

Gehring S, Kullmer U, Koeppelmann S, Gerner P, Wintermeyer P, Wirth S.

World J Gastroenterol. 2006 Sep 28;12(36):5787-92.

PMID:
17007043
[PubMed - indexed for MEDLINE]
Free PMC Article
8.
9.

Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C.

Pavan MH, Pavin EJ, Gonçales Jr FL, Zantut-Wittmann DE.

Braz J Infect Dis. 2011 Sep-Oct;15(5):449-56. Erratum in: Braz J Infect Dis. 2013 Jan-Feb;17(1):122. Wittmann, Denise Engelbrecht Zantut [corrected to Zantut-Wittmann, Denise E].

PMID:
22230851
[PubMed - indexed for MEDLINE]
Free Article
10.

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.

Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, Shelton M, Kerkar N, Galoppo M, Pedreira A, Rodriguez-Baez N, Ciocca M, Lachaux A, Lacaille F, Lang T, Kullmer U, Huber WD, Gonzalez T, Pollack H, Alonso E, Broue P, Ramakrishna J, Neigut D, Valle-Segarra AD, Hunter B, Goodman Z, Xu CR, Zheng H, Noviello S, Sniukiene V, Brass C, Albrecht JK.

J Hepatol. 2010 Apr;52(4):501-7. doi: 10.1016/j.jhep.2010.01.016. Epub 2010 Feb 4.

PMID:
20189674
[PubMed - indexed for MEDLINE]
11.

[Thyroid dysfunctions in children with chronic hepatitis C during interferon alpha-2b therapy].

Kupś-Rzepecka J, Woźniakowska-Gesicka T, Gołabek V.

Przegl Lek. 2011;68(6):311-5. Polish.

PMID:
22039668
[PubMed - indexed for MEDLINE]
12.

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.

Pessôa MG, Cheinquer H, Almeida PR, Silva GF, Lima MP, Paraná R, Lacerda MA, Parise ER, Pernambuco JR, Pedrosa SS, Teixeira R, Sette H Jr, Tatsch F.

Ann Hepatol. 2012 Jan-Feb;11(1):52-61.

PMID:
22166561
[PubMed - indexed for MEDLINE]
13.

The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism.

Carella C, Mazziotti G, Morisco F, Rotondi M, Cioffi M, Tuccillo C, Sorvillo F, Caporaso N, Amato G.

Eur J Endocrinol. 2002 Jun;146(6):743-9.

PMID:
12039693
[PubMed - indexed for MEDLINE]
Free Article
14.

Preliminary study of two antiviral agents for hepatitis C genotype 1.

Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C.

N Engl J Med. 2012 Jan 19;366(3):216-24. doi: 10.1056/NEJMoa1104430.

PMID:
22256805
[PubMed - indexed for MEDLINE]
Free Article
15.

Type 1 diabetes mellitus with dual autoimmune mechanism related to pegylated interferon and ribavirin treatment for chronic HCV hepatitis.

Popescu C, Popescu GA, Arama V.

J Gastrointestin Liver Dis. 2013 Mar;22(1):101-4.

PMID:
23539399
[PubMed - indexed for MEDLINE]
Free Article
16.

[Analysis of thyroid dysfunction and influencing factors in chronic hepatitis C patients treated with peg-IFNa-2a and ribavirin].

Huang YX, Chen XY, Ma LN, Yin JM, Ren S, Guo DD, Zheng YH.

Zhonghua Gan Zang Bing Za Zhi. 2012 Mar;20(3):216-20. doi: 10.3760/cma.j.issn.1007-3418.2012.03.016. Chinese.

PMID:
22475143
[PubMed - indexed for MEDLINE]
17.

Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.

Miyase S, Haraoka K, Ouchida Y, Morishita Y, Fujiyama S.

J Gastroenterol. 2012 Sep;47(9):1014-21. doi: 10.1007/s00535-012-0560-9. Epub 2012 Mar 2.

PMID:
22382633
[PubMed - indexed for MEDLINE]
18.

Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.

Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study [KULDS] Group.

J Gastroenterol Hepatol. 2012 Jul;27(7):1233-40. doi: 10.1111/j.1440-1746.2011.06965.x.

PMID:
22098185
[PubMed - indexed for MEDLINE]
19.

A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C.

Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Rajender Reddy K.

J Hepatol. 2012 May;56(5):1012-8. doi: 10.1016/j.jhep.2011.12.020. Epub 2012 Jan 17.

PMID:
22266603
[PubMed - indexed for MEDLINE]
20.

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM.

N Engl J Med. 2013 Jan 3;368(1):34-44. doi: 10.1056/NEJMoa1208953.

PMID:
23281974
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk